Vice President Corporate Development, Seattle Genetics
Steven Bartz is VP licensing at Seagen and leads the global early stage BD and licensing efforts. Steve and his team look to transact with companies that enable Seagen to maintain its ADC leadership and as well diversify its pipeline of innovative therapeutics.
Prior to joining Seagen in 2020, Steven was at Merck for 19 years. Steven started his career in Merck’s research labs leading teams at two of Merck’s acquisitions, Rosetta and Sirna. He spent the last 9 years of his career at Merck in the BD organization.
Steven completed post-doctoral work at the Fred Hutchinson Cancer Research Center and earned his PHD from the University of Wisconsin.